• Risedronate Sodium: Protocols and Innovations in Bone Metabo

  2026-05-21

  Risedronate Sodium, a potent FPP synthase inhibitor, is redefining both osteoporosis and respiratory research workflows with advanced delivery and quantifiable performance gains. Discover how experimentalists are leveraging nanoformulations and transdermal strategies to enhance reproducibility, bioavailability, and translational impact.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-21

  Wang et al. identify the METTL16-SENP3-LTF axis as a crucial regulator of ferroptosis resistance and tumorigenesis in hepatocellular carcinoma (HCC). This mechanistic insight provides new directions for sensitizing HCC to ferroptosis-based therapies and informs future research on iron metabolism in cancer.

• CARM1-Targeted Peptide Inhibitor Suppresses Breast Cancer Pr

  2026-05-20

  A recent study introduces a selective, cell-permeable peptide inhibitor of CARM1 (Pi-CARM1-TAT), demonstrating significant suppression of breast cancer cell proliferation and tumor growth both in vitro and in vivo. The findings illuminate CARM1 as a druggable epigenetic target and provide a foundation for overcoming endocrine resistance in hormone receptor-positive breast cancer.

• KR-12 Human Antimicrobial Peptide: Applied Protocols & Insig

  2026-05-20

  KR-12 (human) TFA, the minimal LL-37 fragment, offers targeted antimicrobial and anti-biofilm action with low cytotoxicity for research applications. This article translates recent mechanistic findings and reference study protocols into actionable workflows and troubleshooting tips, highlighting KR-12’s versatility in infection and immunomodulation models.

• Ziprasidone HCl in Oncology and Neuroscience: Protocols & Ad

  2026-05-19

  Ziprasidone Hydrochloride bridges neuroscience and oncology, enabling high-fidelity studies of dopaminergic and serotonergic signaling as well as tumor metabolism. This article delivers actionable protocols, interprets key permeability breakthroughs, and offers troubleshooting tips for optimizing your experimental pipeline.

• PPT (Propyl Pyrazole Triol): Selective ERα Agonist for Resea

  2026-05-19

  PPT (Propyl Pyrazole Triol) is a highly selective estrogen receptor alpha (ERα) agonist with >400-fold selectivity over ERβ, enabling precise dissection of ERα-mediated signaling. This article details the molecular mechanism, experimental benchmarks, and key limitations for researchers using this tool in gene expression and hormone receptor studies.

• 25-Hydroxycholesterol Drives Immunosuppressive TAM Programmi

  2026-05-18

  Xiao et al. (2024) uncover how 25-hydroxycholesterol, produced via upregulated CH25H in tumor-associated macrophages, accumulates in lysosomes to activate AMPKα and reprogram macrophage metabolism. This mechanistic insight reveals strategies to disrupt immunosuppression in tumors, enhancing the efficacy of anti-PD-1 therapies.

• Strategic Insights: Z-VEID-FMK in Translational Caspase-6 Re

  2026-05-18

  This thought-leadership article explores Z-VEID-FMK as a precision caspase-6 inhibitor, integrating mechanistic insight, preclinical evidence, and translational strategy. Drawing from recent advances in neuronal apoptosis and inflammatory pain models, it provides actionable guidance for experimental design and positions APExBIO's Z-VEID-FMK as a foundational tool for apoptosis and neuroinflammation research.

• Corynoline Induces Osteosarcoma Apoptosis via Src/JNK Pathwa

  2026-05-17

  A recent study demonstrates that Corynoline, an alkaloid from Corydalis bungeana, exerts anti-osteosarcoma effects by triggering G2/M cell cycle arrest and mitochondrial apoptosis through Src/JNK signaling. These findings highlight a mechanistically precise approach to targeting osteosarcoma cell viability and death, with implications for apoptosis-focused research workflows.

• Tau Ser356 Phosphorylation in Alzheimer’s: Insights from NUA

  2026-05-16

  Taylor et al. (2023) identified tau phosphorylated at serine 356 (p-tau S356) as a Braak stage-dependent marker closely associated with Alzheimer’s disease pathology. Their work demonstrates that selective NUAK kinase inhibition can lower p-tau S356 in both mouse and human brain tissue, revealing differential responses and informing future tau-targeted therapeutic strategies.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Molecular Evide

  2026-05-15

  This study demonstrates that homoharringtonine, a cytotoxic alkaloid, achieves rapid clearance of SARS-CoV-2 from the upper respiratory tract in both animal models and human subjects. The findings underscore homoharringtonine’s translational potential as a broad-spectrum antiviral candidate for future coronavirus epidemics.

• In Vitro Susceptibility of Staphylococci to Mupirocin and No

  2026-05-15

  This study rigorously evaluates the in vitro susceptibility of both meticillin-resistant and meticillin-susceptible staphylococci from dogs to mupirocin and novobiocin. The findings reveal differential antimicrobial activity, highlighting mupirocin’s robust efficacy across resistance profiles and informing choice of veterinary antibiotics for bacterial skin infections.

• Bismuth Subsalicylate in GI Disorder Research: Protocols & I

  2026-05-14

  Bismuth Subsalicylate (1,3,2λ2-benzodioxabismin-4-one) from APExBIO empowers advanced gastrointestinal disorder research through precise prostaglandin inhibition and robust anti-inflammatory action. This guide details optimized workflows, troubleshooting strategies, and key innovations for inflammation and membrane biology assays.

• KR-12 Human Antimicrobial Peptide: Applied Research Workflow

  2026-05-14

  KR-12, the minimal fragment of human cathelicidin LL-37, enables targeted antimicrobial, anti-biofilm, and immunomodulatory experiments with low cytotoxicity. This guide translates the latest mechanistic insights and validated protocols into actionable steps for maximizing research impact using APExBIO's KR-12 (human) TFA.

• O-GlcNAcylation Drives Wnt-Induced Bone Formation via Glycol

  2026-05-13

  This study reveals that O-GlcNAcylation is essential for Wnt3a-stimulated bone formation by promoting aerobic glycolysis in osteoblasts. The findings clarify a key metabolic mechanism underlying Wnt signaling’s anabolic effects and suggest new approaches for osteoporosis research.

16024 records 1/1069 page Next 12345 下5页 Last page